Vulvar pain, itching and burning are common complaints – and often misunderstood. An estimated 10 to 28 percent of all women suffer from vulvodynia in the course of their lives; lichen sclerosus affects around 1.7 percent of the population and is up to 15 times more common than previously diagnosed. Nevertheless, it takes an average of four to seven years for a correct diagnosis to be made. The reason: the overlap between inflammatory dermatoses, functional pain syndromes and oncological precursors requires a systematic clinical assessment, which is often lacking in routine care. The new S3 guideline on lichen sclerosus and a growing body of evidence on the multimodal treatment of vulvodynia offer reliable guidance for the first time.
Autoren
- Tanja Schliebe
Publikation
- GYNÄKOLOGIE PRAXIS
Related Topics
You May Also Like
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Across All Types of Cancer
Four-Legged Medical Assistants – Therapy Dogs in Clinical Settings
- Obesity: More than half of those affected have fatty liver disease
From screening to multimodal intervention with GLP-1-RA or resmetirom
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Plastic surgery and reconstructive microsurgery for DFS